Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma 2021
2021 Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomasNew England Journal of Medicine.  384:1613-1622. 2021
2021 Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant GliomasNeurosurgery Clinics of North America.  32:265-281. 2021
2021 Integrin αvβ3 engagement regulates glucose metabolism and migration through focal adhesion kinase (Fak) and protein arginine methyltransferase 5 (prmt5) in glioblastoma cellsCancers.  13:1-16. 2021
2021 Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies. 2021
2020 Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain TumorsHuman Gene Therapy.  31:1132-1139. 2020
2020 Intraventricular metastatic melanoma: A case report and review of the literatureClinical Case Reports.  8:1757-1764. 2020
2020 Roseomonas gilardii Bacteremia in a Patient with HbSβ0-thalassemia: Clinical Implications and Literature ReviewJournal of Pediatric Hematology/Oncology.  42:e385-e387. 2020
2020 Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of miceCancer Gene Therapy.  27:246-255. 2020
2020 Treatment of pediatric high-grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: A single-institution experience 2020
2020 An update on neurofibromatosis type 1-associated gliomasCancers.  12. 2020
2020 Glioma stem cells and their roles within the hypoxic tumor microenvironmentTheranostics.  11:665-683. 2020
2019 A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibitionOncoImmunology.  8. 2019
2019 Cauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spreadClinical Case Reports.  7:2341-2345. 2019
2019 UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line XenograftsTranslational Oncology.  12:1364-1374. 2019
2019 Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistanceOncogene.  38:6159-6171. 2019
2019 The Impact of Early Corticosteroid Pretreatment before Initiation of Chemotherapy in Patients with Primary Central Nervous System LymphomaNeurosurgery.  85:264-272. 2019
2019 SUMOylation in glioblastoma: A novel therapeutic targetInternational Journal of Molecular Sciences.  20. 2019
2019 SUMOylation promotes survival and integration of neural stem cell grafts in ischemic strokeEBioMedicine.  42:214-224. 2019
2019 Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain TumorsWorld Neurosurgery.  122:e1592-e1598. 2019
2019 Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesisJournal of Neuro-Oncology.  141:289-301. 2019
2019 Artificial intelligence in the management of glioma: Era of personalized medicineFrontiers in Oncology.  9. 2019
2019 Subsequent neoplasms after a primary tumor in individuals with neurofibromatosis type 1Journal of Clinical Oncology.  37:3050-3058. 2019
2019 Treatment-induced remission of medulloblastoma using a chemotherapeutic regimen devoid of vincristine in a child with charcot–marie–tooth diseaseCurrent Oncology.  26:e266-e269. 2019
2018 Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 ExpressionScientific Reports.  8. 2018
2018 FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived XenograftsScientific Reports.  8. 2018
2018 UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenograftsJournal of Neuro-Oncology.  140:209-224. 2018
2018 Quality Initiative to Improve time to Antibiotics for Febrile Pediatric Patients with Potential Neutropenia.Pediatric Quality and Safety.  3:e095. 2018
2018 Drugging SUMOylation for neuroprotection and oncotherapyNeural Regeneration Research.  13:415-416. 2018
2018 Cerebral ischemia increases small ubiquitin-like modifier conjugation within human penumbral tissue: Radiological-pathological correlationFrontiers in Neurology.  8. 2018
2017 Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002Molecular Therapy - Oncolytics.  7:27-36. 2017
2017 Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature 2017
2017 Publication outcomes of abstracts from the American Society of Hematology Annual MeetingAmerican Journal of Hematology.  92:E81-E83. 2017
2017 Oncolytic Virotherapy for the Treatment of Malignant GliomaNeurotherapeutics.  14:333-344. 2017
2017 Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors 2017
2017 Checkpoint proteins in pediatric brain and extracranial solid tumors: Opportunities for immunotherapyClinical Cancer Research.  23:342-350. 2017
2017 Combination strategies enhance oncolytic virotherapyOncotarget.  8:34020-34021. 2017
2016 Protocol for Reducing Time to Antibiotics in Pediatric Patients Presenting to an Emergency Department with Feer and Neutropenia: Efficacy and BarriersPediatric Emergency Care.  32:739-745. 2016
2016 Effect of repeat dosing of engineered oncolytic herpes simplex virus on preclinical models of rhabdomyosarcomaTranslational Oncology.  9:419-430. 2016
2016 Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex virusesNeuro-Oncology.  18:227-235. 2016
2016 Oncolytic virotherapy for pediatric malignancies: future prospects.Oncolytic Virotherapy.  5:73-80. 2016
2015 Pediatric cancer gone viral. Part I: Strategies for utilizing oncolytic herpes simplex virus-1 in childrenMolecular Therapy - Oncolytics.  2:15015. 2015
2015 Pediatric cancer gone viral. Part II: Potential clinical application of oncolytic herpes simplex virus-1 in childrenMolecular Therapy - Oncolytics.  2:15016. 2015
2015 Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomasJournal of Neuro-Oncology.  122:585-593. 2015
2015 Attack of the cancer-killing viruses: Clinical application of oncolytic virotherapy in children 2015
2015 γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia 2015
2014 Oncolytic viral therapy: targeting cancer stem cells.Oncolytic Virotherapy.  2014:21-33. 2014
2014 Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumorsPLoS ONE.  9. 2014
2014 Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitroJournal of Neuro-Oncology.  118:61-72. 2014
2014 The role of Src family kinases in growth and migration of glioma stem cellsInternational Journal of Oncology.  45:302-310. 2014
2013 Pediatric glioma stem cells: Biologic strategies for oncolytic HSV virotherapyFrontiers in Oncology.  3 FEB. 2013
2013 Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of NeuroblastomaPLoS ONE.  8. 2013
2013 Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resectionJournal of Pediatric Hematology/Oncology.  35. 2013
2013 CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV 2013
2012 Hypoxia moderates γ134.5-deleted herpes simplex virus oncolytic activity in human glioma xenoline primary culturesTranslational Oncology.  5:200-207. 2012
2012 Targeting pediatric cancer stem cells with oncolytic virotherapy.Pediatric Research.  71:500-510. 2012
2011 Response to radiation in renal medullary carcinomaRare Tumors.  3:100-103. 2011
2011 Long-term complete response after treatment with cytarabine, vincristine, and prednisone in an infant with refractory multisystem Langerhans cell histiocytosis 2011
2011 Cancer stem cells and pediatric solid tumorsCancers.  3:298-318. 2011
2010 Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma 2010
2009 Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111Journal of Neuro-Oncology.  95:199-209. 2009
2009 Herpes simplex virus oncolytic therapy for pediatric malignanciesMolecular Therapy.  17:1125-1135. 2009
2008 Myelofibrosis in a patient with familial hemophagocytic lymphohistiocytosis 2008
2007 Changing trends of research and treatment in infant neuroblastoma 2007

Principal Investigator On

  • ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Advancing to a Phase 2 Clinical Trial for Pediatric Brain Tumors  awarded by RALLY FOUNDATION
  • Affect of Oxygen Tension on Glioma Stem Cells  awarded by ALABAMA CHILDREN'S HOSPITAL FOUNDATION^
  • Boosting Immunovirotheraphy with Tumor Vaccination to Treat Pediatric Malignant Brain Tumors  awarded by ANDREW MCDONOUGH B+ FOUNDATION
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Engineered Oncolytic Herpes Simplex Virotherapy for Medulloblastomas  awarded by St. Baldrick's Foundation
  • Enhancement of Oncolytic Virotherapy with Tumor Vaccination  awarded by RALLY FOUNDATION
  • Enhancement of lmmunovirotherapy with IDO Inhibition in Pediatric Medulloblastoma  awarded by HYUNDAI HOPE ON WHEELS
  • Evaluation pf Clinically-ready Oncolytic HSV in Pediatric Brain Tumors  awarded by HYUNDAI HOPE ON WHEELS
  • Expansion of G207 Trial  awarded by CANNONBALL KIDS' CANCER FOUNDATION
  • Headstart IV Clinical Study Rider  awarded by NATIONWIDE CHILDREN'S
  • Immune Checkpoint Blockade in Combination with oHSVs for Pediatric Brain Tumors  awarded by American Brain Tumor Association
  • Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Intraventricular Delivery of Engineered Oncolytic Herpes Simplex Virotherapy to Treat Localized and Metastatic Pediatric Brain Tumors  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY
  • Larotrectinib for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Maximizing the Anti-Tumor Immune Response from HSV Immunovirotherapy  awarded by RALLY FOUNDATION
  • Maximizing the Anti-Tumor Immune Response from HSV Immunovirotherapy  awarded by RALLY FOUNDATION
  • Maximizing the Anti-Tumor Immune Response from HSV Immunovirotherapy  awarded by RALLY FOUNDATION
  • NIH COG Phase I Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Overcoming Myeloid Cell-Mediated Immunosuppression to Enhance Immunovirotherapy  awarded by HYUNDAI HOPE ON WHEELS
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Ph1 Study of HSV G207 in Pediatric Malignant Cerebellar Tumors IND 16294 01/05/18  awarded by Food & Drug Administration
  • Ph1 of HSV G207 and Radiation to Treat Pediatric Brain Tumors IND 16294 (12/10/14)  awarded by Food & Drug Administration
  • Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Phase 1 Trial of Engineered HSV G207 in Children with Malignant Cerebellar Brain Tumors  awarded by CANNONBALL KIDS' CANCER FOUNDATION
  • Pilot Study of HSV G207 Alone or with Radiation in Children with Recurrent Brain Tumors  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • Preclinical Testing of Engineered Herpes Simplex Virotherapy in Pediatric Brain Tumors  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • Preclinical Testing of Oncolytic Engineered Herpes Simplex Virus in Medulloblastomas  awarded by American Brain Tumor Association
  • Private Grant  awarded by EISAI, INC.
  • Private Grant  awarded by TREOVIR, LLC ^
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION
  • lmmunovirotherapy to Target Pediatric Brain Tumors  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • Investigator On

  • A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase II Study of Sunitinib in Recurrent or Progressive Brain Tumors in Pediatric and Young Adult Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Randomized, Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Gliomac-UFRA-317  awarded by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD  awarded by CHILDREN'S ONCOLOGY GROUP
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ACTION Trial- Adoptive Cellular Therapy Following Dose-Intensified Temozolomide in Newly-Diagnosed Pediatric High-Grade Gliomas (Phase I)  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • APEC1621SC - PEDIATRIC MATCH PCR - COG FOUNDATION  awarded by CHILDREN'S ONCOLOGY GROUP
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CCOP Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase ll Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis  awarded by St. Jude Children's Research Hospital
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Phase 1-11 Study of MEK 162 for Children with Progressive or Recurrent Cancer and A Phase 11 Study of Children with Low- Grade Gliomas and Other Ras/ RAF/MAP Pathway Activated Tumors  awarded by CHILDREN'S HOSPITAL LA
  • Phase I Study of MEK162 for Children with Progressive or Recurrent Cancer and a Phase II Study of Children with Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors  awarded by Childrens Hospital Los Angeles
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by ONCOCEUTICS INC
  • Private Grant  awarded by SPRINGWORKS THERAPEUTICS ^
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • UAB Research and Education Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Education And Training

  • University of Alabama at Birmingham, Internship
  • University of Alabama at Birmingham, Residency
  • University of Alabama at Birmingham, Postdoctoral Fellowship
  • Doctor of Medicine, Medical College of Georgia 2002
  • Full Name

  • Gregory Friedman